Fuller & Thaler reports 4.53M shares (3.72%) in INDV

Indivior Pharmaceuticals, Inc. ownership disclosure: Fuller & Thaler Asset Management, Inc. reports beneficial ownership of 4,529,583.47 shares of Common Stock, representing 3.72% of the class as reported in Amendment No. 1.

Rhea-AI Filing Summary

Indivior Pharmaceuticals, Inc. ownership disclosure: Fuller & Thaler Asset Management, Inc. reports beneficial ownership of 4,529,583.47 shares of Common Stock, representing 3.72% of the class as reported in Amendment No. 1.

The filing states sole voting power of 4,351,663.47 shares and sole dispositive power of 4,529,583.47. The form is signed by the firm’s Chief Compliance Officer on 05/13/2026.

Insights

Institutional Ownership Analyst

Large institutional stake disclosed: 4.53M shares (3.72%).

Fuller & Thaler reports beneficial ownership of 4,529,583.47 shares, equal to 3.72% of the class as of the amendment. The filing lists 4,351,663.47 shares with sole voting power and 4,529,583.47 shares with sole dispositive power.

Holdings at this scale can matter for shareholder composition; future filings may show position changes. Timing anchors: report header shows 03/31/2026 and signature date 05/13/2026.

Corporate Governance Specialist

Disclosure clarifies control and disposition authorities.

The amendment enumerates voting and dispositive powers, indicating the reporting entity exercises sole control over voting (4,351,663.47) and disposition (4,529,583.47) of the shares it reports. This is standard Schedule 13G/A detail on authority.

Because the reported stake is 3.72%, it falls below a 5% threshold referenced in the form. Any material change in percent or power would appear in subsequent amendments.

Key Figures

Beneficial ownership: 4,529,583.47 shares Percent of class: 3.72% Sole voting power: 4,351,663.47 shares +3 more

6 metrics

Beneficial ownership 4,529,583.47 shares Amount beneficially owned reported on the Schedule 13G/A

Percent of class 3.72% Percent of common stock represented by the reported shares

Sole voting power 4,351,663.47 shares Shares with sole power to vote as stated in Item 4(c)(i)

Sole dispositive power 4,529,583.47 shares Shares with sole power to dispose as stated in Item 4(c)(iii)

Signature date 05/13/2026 Date the amendment was signed by the Chief Compliance Officer

Report header date 03/31/2026 Date appearing on the filing header

Key Terms

Schedule 13G/A, beneficially owned, sole dispositive power, sole voting power

4 terms

Schedule 13G/A regulatory

"Amendment No. 1 and the form header showing beneficial ownership"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

beneficially owned financial

"Item 4(a) Amount beneficially owned: 4,529,583.47"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

sole dispositive power regulatory

"Item 4(c)(iii) Sole power to dispose: 4,529,583.47"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

sole voting power regulatory

"Item 4(c)(i) Sole power to vote or to direct the vote: 4,351,663.47"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Fuller & Thaler report in INDV?

Fuller & Thaler reports beneficial ownership of 4,529,583.47 shares, representing 3.72% of Indivior's common stock according to Amendment No. 1.

How many shares does Fuller & Thaler have voting control over in INDV?

The filing shows sole voting power over 4,351,663.47 shares and shared voting power of 0, as stated in the Schedule 13G/A amendment.

Who signed the Schedule 13G/A amendment for Fuller & Thaler?

The filing is signed by Hanna Zanoni, Chief Compliance Officer, with a signature date of 05/13/2026 on the Amendment No. 1 submission.

Does the filing indicate Fuller & Thaler controls disposition of its INDV shares?

Yes. The form states sole dispositive power of 4,529,583.47 shares and shared dispositive power of 0, reflecting the firm’s reported control over share disposition.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/13/2026 - 04:31 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Indivior Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

45579U109

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 45579U109

1

Names of Reporting Persons

Fuller & Thaler Asset Management, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CALIFORNIA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 4,351,663.47
6	Shared Voting Power 0.00
7	Sole Dispositive Power 4,529,583.47
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,529,583.47

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.72 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Indivior Pharmaceuticals, Inc.
(b)	Address of issuer's principal executive offices: 10710 MIDLOTHIAN TURNPIKE, SUITE 125, NORTH CHESTERFIELD, VA, 23235
Item 2.
(a)	Name of person filing: Fuller & Thaler Asset Management, Inc.
(b)	Address or principal business office or, if none, residence: 411 Borel Avenue, Suite 300, San Mateo, CA 94402
(c)	Citizenship: California corporation
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 45579U109
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 4,529,583.47
(b)	Percent of class: 3.72 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 4,351,663.47
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 4,529,583.47
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Fuller & Thaler Asset Management, Inc.

Signature:	/s/ Hanna Zanoni
Name/Title:	Chief Compliance Officer
Date:	05/13/2026